Which statement best defines destination therapy in LVAD use?

Which statement best defines destination therapy in LVAD use?

• A. LVADs are only a temporary measure until transplant
• B. LVADs can serve as permanent therapy for those not eligible for transplant
• C. LVADs cure heart failure
• D. LVADs are used only for right-sided heart failure

Answer: (B)

Destination therapy means using an LVAD as a long-term solution for patients with advanced heart failure who are not candidates for heart transplantation. This approach provides ongoing mechanical support to the left ventricle, improving blood flow, symptoms, and often quality of life, without the expectation of curing the underlying disease. It’s chosen for people who are not eligible for transplant or who do not pursue it, making the LVAD a permanent therapy rather than a temporary bridge. An LVAD does not cure heart failure; it augments pumping function so the circulation is better supported, but the diseased heart remains. Patients typically need ongoing management, including anticoagulation to reduce clot risk and monitoring for device-related complications. The other statements don’t fit because a device used as destination therapy is not merely a temporary measure until transplant, it doesn’t cure heart failure, and it isn’t limited to scenarios of right-sided heart failure (LVADs specifically support the left ventricle; separate devices or strategies address the right side).

Destination therapy means using an LVAD as a long-term solution for patients with advanced heart failure who are not candidates for heart transplantation. This approach provides ongoing mechanical support to the left ventricle, improving blood flow, symptoms, and often quality of life, without the expectation of curing the underlying disease. It’s chosen for people who are not eligible for transplant or who do not pursue it, making the LVAD a permanent therapy rather than a temporary bridge.

An LVAD does not cure heart failure; it augments pumping function so the circulation is better supported, but the diseased heart remains. Patients typically need ongoing management, including anticoagulation to reduce clot risk and monitoring for device-related complications.

The other statements don’t fit because a device used as destination therapy is not merely a temporary measure until transplant, it doesn’t cure heart failure, and it isn’t limited to scenarios of right-sided heart failure (LVADs specifically support the left ventricle; separate devices or strategies address the right side).